It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FBRX’s FA Score shows that 0 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 5 TA indicator(s) are bullish while FBRX’s TA Score has 5 bullish TA indicator(s).
FBRX (@Biotechnology) experienced а -9.36% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
FBRX is expected to report earnings on Nov 11, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ARRY | FBRX | ARRY / FBRX | |
Capitalization | 2.22B | 8.18M | 27,174% |
EBITDA | 276M | -37.19M | -742% |
Gain YTD | -57.381 | -77.851 | 74% |
P/E Ratio | 26.23 | N/A | - |
Revenue | 1.58B | 0 | - |
Total Cash | 249M | 24.5M | 1,016% |
Total Debt | 730M | N/A | - |
ARRY | FBRX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 99 | |
PRICE GROWTH RATING 1..100 | 65 | 97 | |
P/E GROWTH RATING 1..100 | 30 | 68 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (85) in the Biotechnology industry is in the same range as FBRX (98) in the null industry. This means that ARRY’s stock grew similarly to FBRX’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FBRX (100) in the null industry. This means that ARRY’s stock grew similarly to FBRX’s over the last 12 months.
ARRY's SMR Rating (80) in the Biotechnology industry is in the same range as FBRX (99) in the null industry. This means that ARRY’s stock grew similarly to FBRX’s over the last 12 months.
ARRY's Price Growth Rating (65) in the Biotechnology industry is in the same range as FBRX (97) in the null industry. This means that ARRY’s stock grew similarly to FBRX’s over the last 12 months.
ARRY's P/E Growth Rating (30) in the Biotechnology industry is somewhat better than the same rating for FBRX (68) in the null industry. This means that ARRY’s stock grew somewhat faster than FBRX’s over the last 12 months.
ARRY | FBRX | |
---|---|---|
RSI ODDS (%) | 2 days ago72% | 2 days ago78% |
Stochastic ODDS (%) | 2 days ago88% | 2 days ago76% |
Momentum ODDS (%) | 2 days ago87% | N/A |
MACD ODDS (%) | N/A | 2 days ago76% |
TrendWeek ODDS (%) | 2 days ago80% | 2 days ago85% |
TrendMonth ODDS (%) | 2 days ago76% | 2 days ago85% |
Advances ODDS (%) | 6 days ago81% | 23 days ago75% |
Declines ODDS (%) | 10 days ago90% | 2 days ago85% |
BollingerBands ODDS (%) | 2 days ago86% | 2 days ago88% |
Aroon ODDS (%) | 2 days ago84% | 2 days ago87% |
A.I.dvisor indicates that over the last year, ARRY has been closely correlated with SHLS. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARRY jumps, then SHLS could also see price increases.
Ticker / NAME | Correlation To ARRY | 1D Price Change % | ||
---|---|---|---|---|
ARRY | 100% | +9.82% | ||
SHLS - ARRY | 66% Closely correlated | +3.11% | ||
FSLR - ARRY | 61% Loosely correlated | +3.15% | ||
NXT - ARRY | 59% Loosely correlated | +4.95% | ||
RUN - ARRY | 57% Loosely correlated | +2.71% | ||
AXON - ARRY | 53% Loosely correlated | +1.45% | ||
More |
A.I.dvisor tells us that FBRX and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FBRX and AXON's prices will move in lockstep.
Ticker / NAME | Correlation To FBRX | 1D Price Change % | ||
---|---|---|---|---|
FBRX | 100% | -5.41% | ||
AXON - FBRX | 31% Poorly correlated | +1.45% | ||
ARRY - FBRX | 28% Poorly correlated | +9.82% | ||
CLNN - FBRX | 27% Poorly correlated | +1.09% | ||
CDTX - FBRX | 27% Poorly correlated | +0.86% | ||
PASG - FBRX | 27% Poorly correlated | +1.69% | ||
More |